NYSE$PLX
Protalix Biotherapeutics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a business update on recent corporate and clinical developments.
Protalix reported financial results for the fourth quarter and full year ended December 31, 2019. The company is focused on advancing its clinical pipeline, expanding sales in Brazil of Elelyso®, and leveraging commercial opportunities to expand its global footprint in the treatment of Fabry disease.
- Expanded on strong foundation and entered into a new phase of development as a world-class recombinant therapeutic company
- Positioned for both near- and long-term success
- Three ongoing, fully-enrolled Phase III clinical trials of PRX-102
- Anticipate BLA submission to the U.S. Food and Drug Administration under the Accelerated Approval pathway next quarter
Headline financials
Revenue & EPS history
Protalix · Revenue · Quarterly
$3.78M
Revenue by segment
Protalix · $3.18M total across 1 segment · Q2 2021
- License & R&D$3.18M—100.0%
Forward guidance
Protalix anticipates 2020 to be a banner year as they increase focus on advancing clinical pipeline, expanding Elelyso sales in Brazil, and leveraging commercial opportunities to expand global footprint in Fabry disease treatment.
Tailwinds
- Advancing clinical pipeline
- Expanding sales in Brazil of Elelyso
- Leveraging commercial opportunities to expand global footprint in Fabry disease treatment
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-1.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-6.0%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+15.7%
Q2 2023
Best reaction
-36.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +0.0% | — | |
| Q4 2025 | +1.8% | -23.7% | -16.8% | |
| Q3 2025 | -10.9% | -12.1% | -16.4% | |
| Q1 2025 | +0.0% | +2.4% | -10.8% | |
| Q4 2024 | +9.4% | +11.2% | +16.1% | |
| Q3 2024 | +12.9% | +31.5% | +45.2% | |
| Q2 2024 | -8.7% | -7.7% | +1.0% | |
| Q1 2024 | -8.8% | -9.6% | -10.4% | |
| Q4 2023 | -12.5% | -14.5% | -22.4% | |
| Q3 2023 | -18.9% | -27.6% | -14.1% | |
| Q2 2023 | +15.7% | +15.7% | +13.9% | |
| Q1 2023 | +3.8% | -7.3% | -29.8% | |
| Q4 2022 | +6.6% | +12.6% | +11.0% | |
| Q3 2022 | +0.9% | +1.9% | +10.5% | |
| Q2 2022 | -0.4% | -2.4% | -11.4% | |
| Q1 2022 | +0.9% | +7.5% | +1.9% | |
| Q4 2021 | +0.0% | +40.0% | +10.5% | |
| Q3 2021 | -3.5% | -14.0% | -21.9% | |
| Q2 2021 | +2.2% | +0.0% | -0.7% | |
| Q1 2021 | +0.7% | -1.0% | -24.4% | |
| Q4 2020 | -5.1% | -4.5% | -24.7% | |
| Q3 2020 | -7.9% | -9.3% | +2.0% | |
| Q2 2020 | +2.2% | +3.3% | -6.1% | |
| Q1 2020 | +2.7% | +7.5% | +12.3% | |
| Q4 2019 | -3.0% | -5.1% | +3.8% | |
| Q3 2019 | -5.2% | -8.7% | +34.8% | |
| Q2 2019 | -36.4% | -29.7% | -40.5% | |
| Q1 2019 | -2.7% | -6.8% | -15.9% | |
| Q4 2018 | +1.8% | -6.1% | -12.2% | |
| Q3 2018 | -5.2% | -14.3% | -12.2% | |
| Q2 2018 | -2.0% | +0.0% | -6.0% | |
| Q1 2018 | +2.2% | +12.5% | +15.0% | |
| Q4 2017 | -1.4% | +1.5% | -33.8% | |
| Q3 2017 | -6.6% | -1.4% | -15.1% | |
| Q2 2017 | -4.6% | -12.3% | -4.6% | |
| Q1 2017 | -6.0% | -13.0% | -5.4% | |
| Q4 2016 | -4.7% | -14.1% | -18.0% | |
| Q3 2016 | +12.1% | +34.1% | -26.8% | |
| Q2 2016 | -1.5% | -1.6% | -4.7% | |
| Q1 2016 | -0.6% | — | — | |
| Q4 2015 | +4.7% | — | — | |
| Q3 2015 | -3.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +0.2% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2012 | +1.4% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2011 | -1.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2011 | -9.7% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q2 2010 | +0.1% | — | — | |
| Q1 2010 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro